The significance of antiretroviral-associated acute kidney injury in a cohort of ambulatory human immunodeficiency virus-infected patients
Open Access
- 5 June 2013
- journal article
- research article
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 28 (8), 2073-2081
- https://doi.org/10.1093/ndt/gft210
Abstract
To determine the incidence and significance of acute kidney injury (AKI) after initiating highly active antiretroviral therapy (HAART). A prospective cohort study of 271 consecutively treated HIV-infected patients, initiating first (75) or sequential HAART (196) from January 2008 to June 2011. AKI was diagnosed according to the Risk, Injury, Failure, Loss of kidney function, End-stage renal disease (RIFLE)/Acute Kidney Injury Network (AKIN) criteria, and the risk of progression to chronic kidney disease (CKD) was evaluated. A greater estimated glomerular filtration rate (eGFR) decrease after 1 year was observed for patients initiating a tenofovir disoproxil fumarate (TDF)-based regimen (−6.45 versus +0.98 mL/min/1.73 m2 when compared with patients without TDF; P < 0.01), both in the case of the first (−8.5 versus −2.27; P = 0.04) or successive regimens (−5.3 versus + 1.18 mL/min/1.73 m2; P < 0.01). AKI, as defined, was observed in 10% (28 cases, 6.98 episodes/100 patients-year), mostly stage I (27 cases), in a median time of 6 (3–16.5) months. Four cases (14%), having a worse baseline renal function progressed to CKD, whereas four recovered completely. In the multivariate analysis, AKI was associated with the concomitant use of cotrimoxazole prophylaxis and to low CD4+ count. CKD was diagnosed in 2% (six cases) of patients. Therefore, the overall rate of HAART-associated renal disorders was 11% (30 cases, 7.46 episodes/100 patients-year (95% confidence interval, 6.09–8.83). The initiation of a tenofovir-based regimen is followed by a significant decline in eGFR, although it could be misinterpreted by the concomitant use of cotrimoxazole. A substantial proportion of patients develop AKI, but only a minority progress to CKD. Patients initiating HAART and developing AKI should be carefully monitored for progression of renal disease.This publication has 37 references indexed in Scilit:
- Long-term clinical consequences of acute kidney injury in the HIV-infectedKidney International, 2010
- Prevalence and Factors Associated with Renal Dysfunction Among HIV-Infected PatientsAIDS Patient Care and STDs, 2010
- Impairment in kidney tubular function in patients receiving tenofovir is associated with higher tenofovir plasma concentrationsAIDS, 2010
- Screening for Chronic Kidney Disease in HIV-Infected PatientsAdvances in Chronic Kidney Disease, 2010
- Can we prevent acute kidney injury?Critical Care Medicine, 2008
- Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injuryCritical Care, 2007
- Minor changes in calculated creatinine clearance and anion‐gap are associated with tenofovir disoproxil fumarate‐containing highly active antiretroviral therapyHIV Medicine, 2006
- Epidemiology and Outcomes of Acute Renal Failure in Hospitalized PatientsClinical Journal of the American Society of Nephrology, 2006
- Acute Kidney Injury, Mortality, Length of Stay, and Costs in Hospitalized PatientsJournal of the American Society of Nephrology, 2005
- Efficacy and Safety of Tenofovir DF vs Stavudine in Combination Therapy in Antiretroviral-Naive PatientsA 3-Year Randomized TrialJAMA, 2004